2.01
price down icon1.95%   -0.04
 
loading
前日終値:
$2.05
開ける:
$2.3
24時間の取引高:
12,580
Relative Volume:
0.63
時価総額:
$10.01M
収益:
$1.41M
当期純損益:
$-9.84M
株価収益率:
-0.9389
EPS:
-2.1408
ネットキャッシュフロー:
$-7.85M
1週間 パフォーマンス:
-9.30%
1か月 パフォーマンス:
-18.95%
6か月 パフォーマンス:
-15.90%
1年 パフォーマンス:
-47.38%
1日の値動き範囲:
Value
$1.985
$2.30
1週間の範囲:
Value
$1.945
$2.3443
52週間の値動き範囲:
Value
$1.945
$4.068

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name
名前
Bioline Rx Ltd Adr
Name
セクター
Healthcare (1052)
Name
電話
-
Name
住所
-
Name
職員
24
Name
Twitter
Name
次回の収益日
2026-11-23
Name
最新のSEC提出書
Name
BLRX's Discussions on Twitter

Compare BLRX vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BLRX icon
BLRX
Bioline Rx Ltd Adr
2.01 10.01M 1.41M -9.84M -7.85M -2.1408
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2017-05-18 アップグレード Maxim Group Hold → Buy
2017-02-13 開始されました Rodman & Renshaw Buy
2016-08-12 ダウングレード Maxim Group Buy → Hold
2015-08-17 繰り返されました Maxim Group Buy
2015-07-27 繰り返されました ROTH Capital Buy
2015-06-22 開始されました JMP Securities Mkt Outperform
すべてを表示

Bioline Rx Ltd Adr (BLRX) 最新ニュース

pulisher
Oct 08, 2026

BioLineRx and Hemispherian to present GLIX1 data at SNO meeting - Investing.com

Oct 08, 2026
pulisher
Oct 08, 2026

One covers lab models; another outlines a trial testing an experimental brain tumor treatment. - Stock Titan

Oct 08, 2026
pulisher
Oct 05, 2026

BioLineRx Ltd. SEC Filing (Oct 5, 2026) - Stock Titan

Oct 05, 2026
pulisher
Oct 02, 2026

Biolinerx Stock Price Forecast. Should You Buy BLRX? - StockInvest.us

Oct 02, 2026
pulisher
Oct 02, 2026

BioLineRx Ltd (NASDAQ: BLRX) Share Price, BLRX Stock News, BLRX Share Price & Updates - kalkine.ca

Oct 02, 2026
pulisher
Oct 01, 2026

Current ratio of BioLineRX Ltd. Sponsored ADR – HAN:YP2 - TradingView

Oct 01, 2026
pulisher
Oct 01, 2026

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 - lelezard.com

Oct 01, 2026
pulisher
Sep 30, 2026

YP2 Forecast — Price Target — Prediction for 2027 - TradingView

Sep 30, 2026
pulisher
Sep 25, 2026

BioLineRx Files Form F-1 to Register Resale of 2,023,382 ADSs Linked to August 2026 Warrants - Kalkine Media

Sep 25, 2026
pulisher
Sep 25, 2026

$5.6 million could go to BioLineRx (Nasdaq: BLRX) if all warrants are exercised for cash. - Stock Titan

Sep 25, 2026
pulisher
Sep 24, 2026

Every proposal passed at BioLineRx (BLRX)’s September 23 annual meeting. - Stock Titan

Sep 24, 2026
pulisher
Sep 17, 2026

BioLineRx Ltd (NASDAQ: BLRX) Share Price, BLRX Stock News, BLRX Share Price & Updates - Kalkine

Sep 17, 2026
pulisher
Sep 17, 2026

BioLineRx Ltd.American Depositary Shares (Nasdaq:BLRX) Detailed Stock Data - The Chronicle-Journal

Sep 17, 2026
pulisher
Sep 11, 2026

Diluted net income available to common stockholders of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - TradingView

Sep 11, 2026
pulisher
Sep 10, 2026

Total revenue of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - tradingview.com

Sep 10, 2026
pulisher
Sep 10, 2026

BioLineRx, Hemispherian to present GLIX1 data at EANO meeting - Investing.com

Sep 10, 2026
pulisher
Sep 10, 2026

BioLineRx and Hemispherian to Showcase GLIX1 Glioblastoma Data and Trial Design at EANO 2026 - TipRanks

Sep 10, 2026
pulisher
Sep 10, 2026

A drug candidate cut tumor growth and extended survival in mice. Human testing is enrolling. - Stock Titan

Sep 10, 2026
pulisher
Sep 10, 2026

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) – Company AnnouncementFT.com - Financial Times

Sep 10, 2026
pulisher
Sep 10, 2026

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - Yahoo Finance

Sep 10, 2026
pulisher
Sep 10, 2026

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - PR Newswire

Sep 10, 2026
pulisher
Sep 09, 2026

Long term debt to total assets ratio of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - tradingview.com

Sep 09, 2026
pulisher
Sep 09, 2026

Return on equity % of BioLineRX Ltd. Sponsored ADR – HAM:YP2 - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

BioLineRx (BLRX) sells warrants to fund R&D push - Stock Titan

Sep 09, 2026
pulisher
Sep 09, 2026

BioLineRX Ltd. Sponsored ADR Statistics – HAM:YP2 - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

YP2 Stock Price and Chart — HAM:YP2 - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

YP2 Forecast — Price Target — Prediction for 2027 - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

YP2 Stock Price and Chart — HAM:YP2 - TradingView

Sep 09, 2026
pulisher
Sep 08, 2026

YP2 Stock Price and Chart — HAM:YP2 - TradingView

Sep 08, 2026
pulisher
Sep 08, 2026

YP2 Stock Price and Chart — HAM:YP2 - TradingView

Sep 08, 2026
pulisher
Sep 01, 2026

BLRX: New GLIX1 Data Touts Synergies - Yahoo Finance

Sep 01, 2026
pulisher
Aug 31, 2026

BioLineRx Earnings Call Highlights GLIX1 Momentum - TipRanks

Aug 31, 2026
pulisher
Aug 31, 2026

BioLineRx (NASDAQ: BLRX) Announces $3.3M Net Raise via 480,696 ADSs at $2.78 Each - Kalkine Media

Aug 31, 2026
pulisher
Aug 31, 2026

BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal - TipRanks

Aug 31, 2026
pulisher
Aug 31, 2026

BioLineRx Releases Q2 2026 Financial Results - AlphaStreet

Aug 31, 2026
pulisher
Aug 31, 2026

Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances - Investing.com

Aug 31, 2026
pulisher
Aug 31, 2026

BioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results - TipRanks

Aug 31, 2026
pulisher
Aug 31, 2026

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire

Aug 31, 2026
pulisher
Aug 31, 2026

BioLineRx (BLRX) lines up new ADS and warrant funding round - Stock Titan

Aug 31, 2026
pulisher
Aug 31, 2026

BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ... - Yahoo Finance

Aug 31, 2026
pulisher
Aug 31, 2026

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance

Aug 31, 2026
pulisher
Aug 31, 2026

BioLine RX Ltd (BLRX) JUN/2026 Earning Prediction - Intellectia AI

Aug 31, 2026
pulisher
Aug 29, 2026

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Sahm

Aug 29, 2026
pulisher
Aug 28, 2026

BioLineRx stock falls on $3.75M share offering plan - Investing.com India

Aug 28, 2026
pulisher
Aug 28, 2026

BioLineRx stock falls on $3.75M share offering plan - Investing.com

Aug 28, 2026
pulisher
Aug 28, 2026

BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility - TipRanks

Aug 28, 2026
pulisher
Aug 28, 2026

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Barchart.com

Aug 28, 2026
pulisher
Aug 28, 2026

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire

Aug 28, 2026
pulisher
Aug 28, 2026

BioLineRx (BLRX) lines up $3.75M raise, ends ATM facility - Stock Titan

Aug 28, 2026
pulisher
Aug 28, 2026

BioLineRx raises $3.75 million in registered direct offering - Investing.com

Aug 28, 2026

Bioline Rx Ltd Adr (BLRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$6.58
price down icon 4.22%
$9.94
price down icon 3.21%
$5.53
price down icon 3.66%
$11.27
price down icon 6.16%
$18.60
price down icon 1.74%
WVE WVE
$3.13
price down icon 1.88%
大文字化:     |  ボリューム (24 時間):